YOLFTbeta
Voyager Therapeutics Inc

Voyager Therapeutics Inc

VYGR · NASDAQ · Healthcare / Biotechnology

1.73USD+0.03 (+1.76%)

Price History

Full chart

Market Stats

Previous Close1.70
Open1.70
Day Range1.59 – 1.74
52-Week Range2.61 – 5.55
Volume806.63K
Market Cap165.14M
P/E (TTM)0.00
Forward P/E8.44
EPS-1.81
Dividend Yield0.00%
Beta1.32
50-Day Avg3.21
200-Day Avg3.71

About

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Alfred W. Sandrock Jr., M.D., Ph.D.
  • Employees141
  • Headquarters75 Hayden Avenue, Lexington, MA, United States, 02421, USA
  • Websitehttps://www.voyagertherapeutics.com

Leadership

  • Dr. Alfred W. Sandrock Jr., M.D., Ph.D.President, CEO & Director · b. 1958
  • Ms. Robin SwartzPrincipal Financial Officer, Treasurer, Chief Business Officer & COO · b. 1971
  • Dr. Krystof Bankiewicz M.D., Ph.D.Founder
  • Dr. Mark A. Kay M.D., Ph.D.Founder · b. 1959
  • Ms. Amy QuinlanPrincipal Accounting Officer · b. 1975
  • Mr. Todd Carter Ph.D.Chief Scientific Officer · b. 1970
  • Ms. Trista MorrisonChief Corporate Affairs Officer & Chief of Staff to the CEO · b. 1977
  • Dr. Mathieu Nonnenmacher Ph.D.Vice President of Gene Therapy
  • Mihalis KariolisVice President of Non-Viral Therapeutics

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-017.33M14.22M10.13M7.62M104.39M171.13M37.41M40.91M250.01M80.00M40.37M
Growth (%)----17.96%-28.73%-24.82%+1270.14%+63.93%-78.14%+9.33%+511.16%-68.00%-49.53%
Cost of Revenue4.63M8.90M27.68M42.25M62.26M64.91M119.73M108.75M73.79M6.19M92.17M4.73M132.27M
Gross Profit-4.63M-8.90M17.33M14.22M10.13M7.62M104.39M62.38M37.41M40.91M157.84M80.00M-91.90M
Gross Margin--100.00%100.00%100.00%100.00%100.00%36.45%100.00%100.00%63.13%100.00%-227.62%
Operating Expense2.90M5.47M37.59M55.52M82.00M98.71M156.07M34.99M111.03M91.74M35.82M163.29M39.94M
Operating Income-7.53M-14.37M-20.25M-41.30M-71.86M-91.09M-51.68M27.38M-73.62M-50.84M122.01M-83.29M-131.84M
Operating Margin---116.85%-290.43%-709.06%-1195.63%-49.51%16.00%-196.76%-124.27%48.80%-104.11%-326.56%
EBITDA-134.00K-14.18M-19.65M-40.69M-70.27M-88.98M-48.91M31.20M-68.45M-44.65M138.18M-59.61M-115.52M
EBITDA Margin---113.38%-286.13%-693.32%-1167.84%-46.86%18.23%-182.96%-109.14%55.27%-74.51%-286.12%
Net Income-7.67M-16.32M-29.67M-40.19M-70.70M-88.29M-40.83M36.74M-66.03M-46.41M132.33M-65.00M-119.72M
Net Income Margin---171.18%-282.65%-697.56%-1158.79%-39.11%21.47%-176.49%-113.45%52.93%-81.25%-296.53%
R&D4.63M8.90M27.68M42.25M62.26M64.91M119.73M108.75M73.79M60.76M92.17M127.37M134.67M
R&D as % of Total Revenue--159.68%297.11%614.31%851.88%114.70%63.55%197.21%148.54%36.87%159.21%333.57%
Interest Expense-0332.00K976.00K0000390.00K1.79M---
Interest Expense % of Total Revenue--1.92%6.86%0.00%0.00%0.00%0.00%1.04%4.38%---

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets149.00K11.50M229.46M189.57M184.48M177.03M354.76M261.58M193.85M159.36M351.28M393.05M252.28M
Total Liabilities3.98M10.35M60.38M53.64M50.43M130.58M255.25M107.26M98.80M100.34M114.96M93.29M56.20M
Total Equity-3.83M1.15M169.07M135.92M134.05M46.45M99.51M154.32M95.06M59.02M236.32M299.76M196.08M
Cash135.00K7.04M31.31M36.64M31.53M46.86M86.04M104.44M117.43M98.96M68.80M71.37M65.30M
Total Debt2.93M6.30M----34.17M47.61M44.18M23.13M20.29M43.73M36.50M
Net Debt2.79M-730.00K-31.31M-36.64M-31.53M-46.86M-51.87M-56.83M-73.25M-75.83M-48.51M-27.64M-28.80M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.45M-11.92M41.30M-42.48M-61.35M-15.89M48.67M-96.72M-53.52M-12.51M77.92M-15.31M-132.47M
Investing Cash Flow--3.30M-194.77M47.30M-3.68M26.47M-90.48M113.00M65.91M-7.34M-141.64M-94.86M125.45M
Financing Cash Flow5.72M22.12M177.74M514.00K59.92M4.75M80.99M3.16M612.00K1.11M33.65M114.02M816.00K
Capital Expenditure02.99M1.03M5.03M3.98M4.30M7.72M12.10M1.61M2.49M3.26M3.52M2.60M
Free Cash Flow-5.45M-14.91M40.27M-47.51M-65.33M-20.19M40.95M-108.81M-55.13M-15.00M74.66M-18.83M-135.06M
Dividends Paid--000--------
FCF to OCF100.00%125.07%97.51%111.84%106.50%127.10%84.14%112.51%103.01%119.91%95.82%123.00%101.96%
Dividend Paid to FCF--0.00%0.00%0.00%--------

Earnings

Report DateDec 17, 2015Mar 17, 2016May 12, 2016Aug 11, 2016Nov 10, 2016Mar 15, 2017May 9, 2017Aug 8, 2017Nov 2, 2017Mar 14, 2018May 10, 2018Aug 7, 2018Nov 7, 2018Feb 26, 2019May 7, 2019Aug 9, 2019Nov 6, 2019Mar 3, 2020May 6, 2020Aug 10, 2020Nov 9, 2020Feb 25, 2021May 10, 2021Aug 9, 2021Nov 2, 2021Mar 8, 2022May 4, 2022Aug 4, 2022Nov 8, 2022Mar 7, 2023May 9, 2023Aug 3, 2023Nov 6, 2023Feb 28, 2024May 13, 2024Aug 6, 2024Nov 12, 2024Feb 26, 2025May 6, 2025Aug 6, 2025Nov 10, 2025Mar 10, 2026May 7, 2026Aug 6, 2026Nov 9, 2026
EPS Estimate-0.31-0.55-0.50-0.33-0.41-0.45-0.53-0.59-0.71-0.72-0.61-0.66-0.76-0.710.58-0.80-0.67-0.81-0.81-0.690.20-0.57-0.66-0.68-0.73-0.33-0.34-0.42-0.41-0.551.26-0.56-0.60-0.29-0.42-0.40-0.40-0.35-0.44-0.52-0.52-0.51-0.53-0.55-0.41
EPS Actual-5.25-0.67-0.29-0.37-0.35-0.57-0.65-0.73-0.89-0.40-0.63-0.80-0.63-0.70-0.810.29-0.41-0.34-0.66-0.232.27-0.43-0.58-0.80-0.670.15-0.56-0.500.45-0.612.94-0.51-0.591.25-0.20-0.18-0.16-0.59-0.53-0.57-0.47-0.47-0.47-0.40-
Surprise-1593.55%-21.82%42.00%-12.12%14.63%-26.67%-22.64%-23.73%-25.35%44.44%-3.28%-21.21%17.11%1.41%-239.66%136.25%38.81%58.02%18.52%66.67%1035.00%24.56%12.12%-17.65%8.22%145.45%-64.71%-19.05%209.76%-10.91%133.33%8.93%1.67%531.03%52.38%55.00%60.00%-68.43%-20.45%-9.62%9.62%7.93%11.32%27.27%-
TimingAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap165.14M
Enterprise Value93.69M
Trailing P/E0.00
Forward P/E8.44
PEG Ratio0.00
Price / Sales4.79
Price / Book1.15
EPS-1.81
Book Value2.52
Revenue (TTM)34.46M
Gross Profit (TTM)-81.60M
EBITDA-109.87M
Profit Margin0.00%
Operating Margin-833.87%
Return on Equity-54.09%
Return on Assets-27.34%
Shares Outstanding61.62M
Shares Float44.47M
Beta1.32
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 12 analystsTarget 14.89
  • Strong Buy
    11
  • Buy
    1

Ownership Breakdown

Institutions
57.87%
Insiders
14.84%
Retail / Other
27.29%

Top Institutional Holders

  • BlackRock Inc
    5.57M9.04%
  • Millennium Management LLC
    4.44M7.21%
  • Armistice Capital, LLC
    3.50M5.68%
  • Vestal Point Capital LP
    3.00M4.87%
  • Vanguard Capital Management, LLC
    2.28M3.71%
  • Opaleye Management Inc
    1.19M1.92%
  • Erste Asset Management GmbH
    1.10M1.78%
  • Geode Capital Management, LLC
    1.05M1.70%
  • Two Sigma Investments LLC
    948.52K1.54%
  • State Street Corp
    948.23K1.54%
  • Dimensional Fund Advisors, Inc.
    838.18K1.36%
  • Citadel Advisors Llc
    784.07K1.27%
  • Vanguard Portfolio Management, LLC
    725.77K1.18%
  • Morgan Stanley - Brokerage Accounts
    681.71K1.11%
  • Renaissance Technologies Corp
    578.02K0.94%
  • Sphera Funds Management Ltd.
    469.76K0.76%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.67M2.71%
  • iShares Russell 2000 ETF
    1.36M2.20%
  • Fidelity Small Cap Index
    571.14K0.93%
  • iShares Russell 2000 Value ETF
    484.77K0.79%